ABVX Stock Analysis: Abivax American Depositary | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.491m USD | 12M Return: 1764.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 231M
Warnings
Tailwinds
Seasonality 2.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abivax SA is a French clinical-stage biotechnology company founded in 2013 and headquartered in Paris, focused on developing therapeutics that modulate the bodys natural immune regulatory mechanisms to treat chronic inflammatory diseases. Its lead candidate, obefazimod, is in Phase 3 trials for moderately to severely active ulcerative colitis (UC) and Phase 2b trials for Crohns disease-two of the principal forms of inflammatory bowel disease (IBD). As a clinical-stage biotech, Abivax has no commercialized products, meaning its value is tied primarily to R&D outcomes and clinical trial progression; the company listed on NASDAQ in October 2023 and is classified within the Health Care sectors Biotechnology sub-industry.
- Obefazimod Phase 3 ulcerative colitis readout approaches
- Cash burn accelerates as commercialization nears
- UC competition intensifies from Pfizer etrasimod approval
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA 60.95 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -259.7m > Net Income -537.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.3m) vs 12m ago 25.03% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 6.46%; Δ -6.46% > 0%) |
| Interest Coverage Ratio: -14.99 > 6 (EBIT TTM -383.0m / Interest Expense TTM 25.5m) |
| A: 0.82 (Total Current Assets 513.2m - Total Current Liabilities 62.2m) / Total Assets 547.1m |
| B: -1.40 (Retained Earnings -764.3m / Total Assets 547.1m) |
| C: -1.07 (EBIT TTM -383.0m / Avg Total Assets 357.0m) |
| D: 3.65 (Book Value of Equity 429.6m / Total Liabilities 117.5m) |
| Altman-Z'' = -2.52 = D |
As of July 08, 2026, the stock is trading at USD 142.17 with a total of 1,354,718 shares traded. Over the past week, the price has changed by +9.78%, over one month by +42.23%, over three months by +27.37% and over the past year by +1764.71%.
Current recommended Stop Loss: 121.00 (which is 14.9% or 2 ATR below the current price).
Abivax American Depositary has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy ABVX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 160.1 | 12.6% |
Market Cap EUR = 10.0b (11.5b USD * 0.8742 USD.EUR)
P/S = 2335.4673
P/B = 23.5966
Revenue TTM = 0.0 EUR
EBIT TTM = -383.0m EUR
EBITDA TTM = -381.8m EUR
Long Term Debt = unknown (none)
Short Term Debt = 29.4m EUR (from shortTermDebt, last fiscal year)
Debt = 47.3m EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 1.45m
Net Debt = -430.1m EUR (calculated: Debt 47.3m - CCE 477.4m)
Enterprise Value = 9.61b EUR (10.0b + Debt 47.3m - CCE 477.4m)
Interest Coverage Ratio = -14.99 (Ebit TTM -383.0m / Interest Expense TTM 25.5m)
EV/FCF = -37.01x (Enterprise Value 9.61b / FCF TTM -259.8m)
FCF Yield = -2.70% (FCF TTM -259.8m / Enterprise Value 9.61b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.03m) / Revenue TTM)
Tobins Q-Ratio = 17.57 (Enterprise Value 9.61b / Total Assets 547.1m)
Interest Expense / Debt = 53.97% (Interest Expense 25.5m / Debt 47.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -302.6m (EBIT -383.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.25 (Total Current Assets 513.2m / Total Current Liabilities 62.2m)
Debt / Equity = 0.11 (Debt 47.3m / totalStockholderEquity, last quarter 429.6m)
Debt / EBITDA = 1.13 (negative EBITDA) (Net Debt -430.1m / EBITDA -381.8m)
Debt / FCF = 1.66 (negative FCF - burning cash) (Net Debt -430.1m / FCF TTM -259.8m)
Total Stockholder Equity = 336.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -150.7% (out of range, set to none)
RoE = -159.7% (Net Income TTM -537.9m / Total Stockholder Equity 336.9m)
RoCE = -78.98% (EBIT -383.0m / Capital Employed (Total Assets 547.1m - Current Liab 62.2m))
RoIC = -58.83% (negative operating profit) (NOPAT -302.6m / Invested Capital 514.3m)
WACC = 17.63% (E(10.0b)/V(10.1b) * Re(17.71%) + (debt cost/tax rate unavailable))
Discount Rate = 17.71% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 75.73%
[DCF] Fair Price = unknown (Cash Flow -259.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.91 | Chg30d=-46.20% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.69 | Chg30d=-21.67% | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=-3.64 | Chg30d=-3.03% | Revisions=+12% | GrowthEPS=+34.9% | GrowthRev=+1528.8%
EPS next Year (2027-12-31): EPS=-3.26 | Chg30d=-28.40% | Revisions=+12% | GrowthEPS=+10.4% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: +24% (up=9, down=5)